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ABSTRACT. Aujeszky's disease (AD) (or Pseudorabies) is an important viral disease of swine causing neurological signs in 
neonatal pigs, respiratory problems in fatteners and reproductive disorders in breeding stock. Swine is the only natural host of 
Aujeszky's disease virus (ADV) and the only species that can survive its infection. Its transmission is mainly through nose-to-nose 
contact, but several other ways may apply. Both antibody- and cell-mediated immune responses occur following ADV infection, 
while maternal immunity can protect the pigs depending on their level and the virulence of the infecting strain. Virus glycoproteins 
may, also, play a role in immunity with that of gC and gD being the most important. Prevention and control of ADV is based on 
proper vaccination and biosecurity measures, while eradication has been practiced in various ways depending on the situation. 
The current vaccines are based on deletion of certain proteins and are effective. Despite the fact that the disease has been eradicated 
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from many developed countries, AD is still endemic in Greece. Findings of recent emergence of AD in Greek farms and the 
possibility of its eradication are discussed. 
Keywords: Aujeszky's Disease, epidemiology, immunity, control, vaccination 
ΠΕΡΙΛΗΨΗ. Η νόσος του Aujeszky είναι μια σοβαρή ιογενής νόσος του χοίρου η οποία για πρώτη φορά περιγράφηκε το 
1813 στα βοοειδή. Η νόσος του Aujeszky παρουσιάζει παγκόσμια εξάπλωση, αν και έχει εκριζωθεί από αρκετές αναπτυγμένες 
χώρες όπως είναι η Γερμανία, η Αυστρία, η Σουηδία, η Ολλανδία, η Δανία, το Βέλγιο και το Ηνωμένο Βασίλειο. Στην Ελλάδα, 
η νόσος εμφανίζεται ενδημική και παρά το γεγονός ότι ο ιός δεν προκαλεί σοβαρά προβλήματα στις κτηνοτροφικές μονάδες 
τα τελευταία 20 χρόνια. Δυστυχώς, όμως, η διακοπή των εμβολιασμών ως αποτέλεσμα της πρόσφατης οικονομικής κρίσης, 
έχει επαναφέρει το πρόβλημα της νόσου ξανά στο προσκήνιο. Ο χοίρος είναι φυσικός ξενιστής του ιοΰ και μπορεί να επιβιώσει 
μετά από προσβολή. Η μετάδοση του γίνεται κυρίως με κοντινή επαφή, ωστόσο αρκετοί άλλοι τρόποι ενοχοποιούνται. Τόσο 
η χυμική όσο και η κυτταρική ανοσία ενεργοποιούνται κατά τη μόλυνση με τον ιό, ενώ η μητρική ανοσία μπορεί να παρέχει 
αποτελεσματική προστασία στα χοιρίδια, πάντα σε σχέση με τα επίπεδα της και το λοιμογόνο στέλεχος. Οι γλυκοπρωτεϊνες 
του ιού παίζουν, επίσης, ρόλο στην ανοσία με κυριότερο αυτό των gC και gD. Η πρόληψη και ο έλεγχος της νόσου βασίζεται 
στους τακτικούς εμβολιασμούς και σε μέτρα βιοασφάλειας, ενώ η εκρίζωση της έγινε με διάφορους τρόπους ανάλογα με την 
κατάσταση στην περιοχή. Η ανοσοποίηση του χοίρου απέναντι στον ιό μπορεί να επιτευχθεί με τη χρησιμοποίηση ελαττωμένης 
λοιμογόνου δύναμης ζωντανών ή αδρανοποιημένων εμβολίων. Η ανάπτυξη της γενετικής μηχανικής οδήγησε στην παρασκευή 
εμβολίων, τα οποία αποτελούν σημαντικό όπλο για την αντιμετώπιση και τον έλεγχο της νόσου. Σε ό,τι αφορά την Ελλάδα, 
παρουσιάζεται ένα σύντομο ιστορικό και συζητείται η πιθανότητα εκρίζωσης του νοσήματος. 
Λέξεις ευρετηρίασης: Νόσος του Aujeszky, επιδημιολογία, ανοσία, έλεγχος, εμβολιασμός 
EPIDEMIOLOGY 
ADV is spread all over the world, in parts of 
Europe, Southeast Asia and America. The virus has, 
also, been detected in Cuba, Samoa and Rwanda 
(Center for Food Security & Public Health 2006). In 
Europe, AD has been eradicated in Germany, Austria, 
Sweden, The Netherlands, Denmark, Belgium and the 
United Kingdom, while it has never been reported in 
countries such as Norway, Finland and Malta (Pejsak 
and Truszczynski 2006). In the United States of 
America, after application of an eradication program, 
all states were classified as free of the disease since 
June 2007. Canada and New Zealand are, also, free of 
ADV (Center for Food Security & Public Health 
2006). Although ADV has been eradicated from many 
countries throughout the world, the virus is still present 
in populations of wild boar or feral swine. Therefore, 
these populations should be considered as potential 
ADV source of infection for domestic pigs. In 
countries that are free of ADV, vaccination is prohi­
bited. Greece belongs to the countries where the 
disease is enzootic. According to an old serological 
survey in pigs in 1969, 20.8% of the collected samples 
from several regions of Greece were positive to 
antibodies against ADV. In 1983, there was an extreme 
increase in AD cases in the pig population following 
the import of breeding animals (Papatsas et al. 1995, 
Papadopoulos et al. 1996). 
Swine is the only natural host of the virus, 
although ADV can infect a large number of species 
including cattle, sheep, goats, cats, dogs and foxes (in 
fur farms) as well as wildlife (raccoons, opossums, 
skunks and rodents). Infections in horses are rare 
(Center for Food Security & Public Health 2006). 
Despite an anecdotal report about three dubious cases 
of Swine Herpesvirus-1 (SHV-1) infections in man 
(Tischer et al. 2010), there is no evidence that it can 
infect humans and higher primates (Mettenleiter 
2000). ADV causes neurologic disease, characterized 
by severe pruritus and encephalitis leading to death, in 
species other than pigs. The fact that the pig is the only 
species that can survive an ADV infection means that 
eliminating the virus from swine can lead to era­
dication of the disease (Mettenleiter 2000). Dead-end 
hosts such as dogs, cats or wildlife animals may trans­
mit ADV from an infected herd to another, although 
these animals survive only 2-3 days after being infected. 
ADV can be transmitted between swine most often 
via direct (nose to nose) contact (Pensaert and Kluge 
1989). Transmission via inhalation of aerosolized virus 
can, also, occur. Contact with contaminated vaginal 
mucosa or semen is another likely way of infection 
during breeding. The fact that only a number of 
animals in a farm become infected with ADV supports 
the opinion that the virus is not as contagious as it was 
thought to be. The percentage of infected animals can 
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vary between 10% and 90% (Pejsak and Truszczynski 
2006). However, during a primary outbreak of ADV in 
an immunologically naïve herd, the virus can spread as 
fast as within a week, causing abortions in pregnant 
sows, deaths of all newborn piglets, reduced growth 
and respiratory distress in f attener s (Kritas 1994). 
ADV seems to be stable under various environ-
mental conditions. It can persist for up to 7 hours in air 
(with a relative humidity of >55%) and it may travel 
through aerosols for up to 2 km depending on weather 
conditions. The virus can, also, survive for up to 7 hours 
in non-chlorinated water, for 3 days in nasal washings 
and for 4 days in straw bedding. ADV is inactivated by 
drying, sunlight and high temperatures (>37°C) due 
to the presence of a lipid envelope acquired from the 
host cell (Pejsak and Truszczynski 2006). 
IMMUNITY 
Infection of pigs with ADV results in an immune 
response, which provides clinical protection to rein-
fection with a virulent strain. Several factors seem to 
be involved in this immune response (Nauwynck 1997). 
Interferon and spontaneous cytotoxicity by natural 
killer cells seem to participate in the early steps follow-
ing infection (Martin and War die 1984, Wittman and 
Ohlinger 1985). 
Antibodies against ADV can be demonstrated by 
serum neutralization test or by ELISA in the serum of 
pigs starting at 5-10 days post infection. These anti-
bodies belong to IgM or IgG subclasses. IgM anti-
bodies show a peak around 7 to 15 DPI and diminish 
to undetectable levels around 14 to 25 DPI. IgG anti-
bodies reach their maximum around 14 DPI and 
persist for several months. IgA antibodies may, also, 
be detected from 10 DPI with a maximal titer at 13 
DPI. In excretions such as saliva and tears, only IgM 
and IgA antibodies have been detected from 6 to 8 DPI 
and they reach a peak around 8 tol5 DPI (Rodak et al. 
1987, Kimmanetal 1992a). 
Neonatal piglets with colostrum-derived anti-
bodies usually have 12-16 times higher serum neutrali-
zation (SN) titers than their mother (McFerran and 
Dow 1973, Kritas 1994). The SN titers of the pigs may 
range from 2 to 512 and seem to be higher in the litters 
from sows vaccinated with inactivated vaccine com-
pared to the litters from sows vaccinated with live 
vaccine (Andries et al. 1978, Kritas 1994). The half-life 
of the colostrum-derived antibodies is 10-13 days. 
Maternally derived antibodies persist in the blood until 
8-14 weeks of age and may interfere with the formation 
of antibodies at vaccination (Pensaert et al. 1982, Van 
Oirschot and De Leeuw 1985). High SN titers (272-
354) were able to protect neonatal pigs against disease 
and almost entirely against neural invasion and spread 
upon challenge with a virulent strain of ADV (Kritas 
et al. 1997a, 1999a). On the other hand, low SN titers 
(2-3) offered clinical protection, but did not protect 
pigs against neuroinvasion, particularly via the 
olfactory pathway, which is readily accessible to the 
virus due to pigs anatomy (Kritas et al. 1997a, 1999a). 
Suckling pigs with maternal antibodies and pigs 
immune after vaccination are protected against clinical 
disease. However, there is no definite correlation 
between antibody titers and protection. While some 
pigs with undetectable SN titers may be protected 
against disease, others with detectable SN titers may 
not (Andries et al. 1978, Van Oirschot and Gielkens 
1984, Van Oirschot et al. 1984, Martin et al. 1986). The 
level of maternal antibodies and the virulence of the 
infecting strain may both play a role concerning the 
protection (Kritas et al. 1997,1999). Besides, it is not 
always necessary that protective antibodies are neutra-
lizing. Kritas and co-workers, after passive admini-
stration of non-neutralizing monoclonal antibodies, 
had shown that antibodies, are involved in protective 
mechanisms of the nervous tissue of the host species 
against spread of ADV, and particularly within the 
trigeminal pathway (Kritas et al. 1999c). In addition, it 
appears that there is no relation between in vitro 
neutralizing ability of antibodies and the protection 
that they provide against ADV spread within swine 
nervous system (Kritas et al. 1999c). 
Antibody-dependent complement mediated lysis 
of ADV-infected cells and antibody-dependent cell-
mediated cytotoxicity (ADCC) have been demon-
strated (Ashworth at al. 1979, Martin et al. 1984,1986, 
Wittmann and Ohlinger 1985). The appearance of 
ADCC coincides with the appearance of IgG in the 
serum (Wittman and Ohlinger 1985). Neutrophils, 
lymphocytes and monocytes are involved in ADCC 
(Ashworth at al. 1979). 
Cytotoxic T-lymphocytes, also, seem to be involved 
in the immune response against ADV. Zuckermann et 
al. (1990) showed that infection of pigs with ADV 
results in the appearance of cytotoxic T-lymphocytes 
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specific against ADV proteins. 
Glycoproteins have been identified as the major 
antigenic proteins of ADV (Todd et al. 1987). Glyco­
protein gC seems to be a major immunogen of ADV, 
since in sera of pigs that recovered from ADV 
infection, a major fraction of the neutralizing activity 
was directed against gC (Ben-Porat et al. 1986). 
Monoclonal antibodies against gC may neutralize 
ADV without complement (Humpl et al. 1984, 
Wathen et al. 1985, Marchioli et al. 1988) and passive 
immunization with some anti-gC monoclonal anti­
bodies protects pigs against lethal ADV infections 
(Marchioli et al. 1988). Experiments have shown that 
gC is more important than gE, gl or gG with regard to 
the induction of cytotoxic Τ lymphocytes of pigs 
(Zuckermann et al. 1989b, 1990). In mice, active 
immunization with a gC mutant was markedly less 
effective in eliciting neutralizing antibodies, cytotoxic 
T-lymphocytes and protection against challenge com­
pared to immunization with gE-, gl- or gG-negative 
mutants (Zuckermann et al. 1989b, 1990). 
Glycoprotein gD is, also, a major immunogen of 
ADV. Monoclonal antibodies against gD can neutra­
lize ADV without complement (Eloit et al. 1988, Coe 
and Mengeling 1990) and can passively protect pigs 
against lethal ADV infections (Marchioli et al. 1988). 
Active immunization of pigs with gD resulted in 
production of neutralizing antibodies and conferred 
protection against ADV infection (Marchioli et al. 
1987, Mukamoto et al. 1991). Suckling piglets born 
from sows previously immunized with gD glycoprotein 
had neutralizing antibodies in their blood and were 
protected against virulent virus (Mukamoto et al. 
1991). 
Glycoprotein gB is, also, involved in the develop­
ment of immunity against ADV. In sera from infected 
pigs, a fraction of the neutralizing activity was directed 
against gB (Ben-Porat et al. 1986). Monoclonal anti­
bodies against gB may neutralize ADV without 
complement (Wittmann and Rziha 1989) and may 
confer passive protection to pigs against lethal ADV 
infection (Marchioli et al. 1988). 
Glycoprotein gE seems to play a less important 
role than gC and gB in immunity against ADV. Ben-
Porat and co-workers (1986) have shown that 
convalescent pig sera have no or little neutralizing 
activity against gE. Monoclonal antibodies directed to 
gE neutralize ADV in the presence of complement 
(Eloit et al. 1988). Passively administered anti-gE 
monoclonal antibodies protected mice against ADV 
lethal infection (Fuchs et al. 1990), while no data are 
available in pigs. 
Anti-gl monoclonal antibodies do not neutralize 
virus in the absence of complement (Eloit et al. 1988). 
Glycoprotein gG does not induce neutralizing 
antibodies and immunization of mice with gG, it did 
not protect against lethal ADV infections (Thomsen 
et al. 1987). 
PREVENTION AND CONTROL 
The prevention strategy against AD is 
characterized by control measures such as stamping 
out infected herds, test-and-removal of infected pigs, 
vaccination programs or a combination of these above 
measures (Stegeman 2000). These are escorted by 
restriction of swine movements, decontamination and 
disinfection of material and equipment, biosecurity 
procedures for persons with access to pigs and faci­
lities, as well as rat control strategies. Domestic 
animals other than swine, such as dogs and cats, should 
be kept out of the facilities, as they may be infected 
with the virus and transfer it to the herd. 
However, the principal control measures depend 
on the situation found in every country or area: 
1. In countries free of ADV, depopulation of any 
infected herd is the only choice, in addition to strict 
biosecurity and prevention measures (Pejsak and 
Truszczynski 2006). 
2. In countries or areas not yet free of ADV, but 
with the intention to become free, primary reduction 
of the virus spread by systemic vaccinations with DIVA 
(Differentiating Infected from Vaccinated Animals) 
vaccines at least for 3 years is necessary. All breeding 
animals, as well as the nursery pigs, need to be regular­
ly vaccinated until less than 10% of the sows and none 
of the fattening pigs are tested infected. Intensive 
testing of the animals for the presence of virulent ADV 
with a differentiating ELISA and their removal will 
eventually establish an ADV-free status (Pejsak and 
Truszczynski 2006). 
3. In some countries, vaccination is not followed by 
the removal of positive animals. In that case, although 
AD might be present, there are no clinical signs of the 
disease. The application of a vaccination program in 
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those countries is crucial for the control of the disease. 
Vaccination against ADV will "keep down" the 
manifestation of typical clinical signs without eradi­
cating the disease (Papatsas et al. 1995). 
VACCINATION 
The cornerstone for the control of AD is 
vaccination. In general, vaccination reduces the clinical 
signs of ADV, although it does not prevent the spread 
and the development of latent infection by the virulent 
virus. The aim of vaccination in an eradication cam­
paign is not only to induce clinical protection, but 
primarily to stop transmission of infections within and 
between herds by inducing herd immunity. Both 
attenuated and inactivated vaccines can be used 
(Kritas 1994). In ADV endemic areas, it is strongly 
recommended that all newly induced breeding animals 
in the herd should be vaccinated, while breeding 
animals must be vaccinated regularly. In addition, 
piglet vaccination can further assist against the 
circulation of the virus in the herd. Vaccination of pigs 
must be implemented at 10 and 14 weeks of age, if they 
are born to vaccinated sows, or at 6 and 10 weeks of 
age, if they are born to unvaccinated ones (Pejsak and 
Truszczynski 2006). 
The development of marker vaccines and the use 
of diagnostic tests (differential ELISA) can play an 
important role in disease eradication and control 
programs, as it was determined in the ADV eradi­
cation program in the U.S. (Foley et al. 2005). During 
that campaign, the use of gene-deleted vaccines in 
conjunction with diagnostic tests was able to differen­
tiate infected from vaccinated animals, in a strategy 
that finally led to eradication of the disease from swine 
herds (Foley et al. 2005). In The Netherlands, in which 
an eradication campaign was developed in 1993, ADV 
was eradicated in 2002, as shown by the absence of gE-
positive pigs (Bouma 2005). 
The development of genetically engineered 
vaccines against ADV has been one of the most 
important factors in the control of the disease (Kritas 
et al. 1997b). Such vaccines are produced by the 
deletion of specific genes from the genome of the virus. 
The deleted genes encode certain proteins that 
determine the virulence of the strain, while they are 
not responsible for the induction of immunological 
response. Although the role of gE is not fully esta­
blished, it is believed that gE plays an important role 
in the transmission of ADV between cells and the 
movement of ADV in the neurons. In addition, TK 
enzyme is necessary for the replication of ADV in the 
neurons (Kit et al. 1985, Tenser 1991, Kritas et al. 
1999b). Therefore, deletion of both these proteins 
results in a high degree of vaccine attenuation and a 
live vaccine safe for the pigs. Besides genetically 
engineered deletion mutant vaccines, there are live 
vaccines containing gE-strains that have been atte­
nuated by natural methods, such as the continuous 
passages through cell cultures (Bartha strain). In 
recent years, the emergence of DNA vaccines may play 
an important role in the prevention of ADV infection 
in the future. According to Rooij et al. (2005), the 
DNA vaccination with a plasmid encoding gD of PRV 
in pigs provides protective immunity against the 
infection with a wild virus strain. 
The situation in Greece and the possibility of a 
national eradication program. 
Up to 1973, sporadic cases of AD in bovine, sheep 
and mink had been diagnosed in Greece. According to 
a serological survey in pigs from several regions of 
Greece in 1969, 20,8% of the collected samples was 
positive to antibodies against ADV. The first clinical 
report with virus isolation in this species was on May 
1974. Two more clinical cases with high mortality of 
suckling piglets had been reported on January 1976 
and February 1977. In 1983, scattered outbreaks of the 
disease in all territory had followed the import of 
breeding animals from other European countries. The 
first measures were isolation of the affected herds and 
vaccination of all healthy herds with inactivated or 
attenuated vaccines (Papadopoulos 1989, Papatsas et 
al. 1995, Papadopoulos et al. 1996). 
Greece has many important advantages over 
several European countries, which had already 
eradicated ADV (Papadopoulos et al. 1996): 
• The low density of the pig population (7 pigs/km2 
in Greece, when in Holland it is 400 pigs/km2, in 
Belgium 230 pigs/km2, in Germany 73 pigs/km2, in 
Italy, Portugal, Spain and France between 20 and 30 
pigs/km2). 
• The type of the units is principally farrow-to-
finish having their own feed mill. Thus, entrance of 
virus in the farms can be better prevented when 
compared to the fattening type of units. 
• As a country that imports most of its breeding 
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stock, an ADV-free status of animals can be required 
from breeder countries. 
• Vaccinations with live or inactivated gE" 
vaccines are regularly applied in the majority of the 
organized farms. 
Unfortunately, no national strategies for the 
eradication of ADV have ever been applied in Greece. 
Vaccination against ADV supresses the manifestation 
of typical clinical signs. This fact combined with the 
recent economical crisis has led some farmers to 
abandon vaccination against ADV. It is important to 
keep in mind that vaccination does not eliminate the 
virus and that latent virus will "come up" in the 
population when a "chance" will occur. Indeed, the 
presence of a virulent ADV strain was recorded in 
many farms requiring health management assistance 
after non-response to intensive treatments (Kritas et 
al. 2011). All these farms had a history of interruption 
in their AD vaccination program. In most of these 
cases, weight gain depression and respiratory signs in 
fatteners, or manifestation of reproductive problems 
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were observed (Kritas personal communication). 
Based on our health management experience, we 
recommend and encourage farmers on the following 
main issues: 
• Systematic application of gE" vaccine (live or 
inactivated) on the breeding stock and the fatteners 
(live vaccine) of the farm. 
• The purchase of only gE" replacement stock. 
• Supportive measures such as application of "all-
in, all-out" system, strict biosecurity/ quarantine 
measures for animals and visitors, prevention of stressy 
conditions. 
• In the case that farmers wish to quit ADV 
vaccination, this should be done not based on clinical 
or post mortem findings, but on intense laboratory 
testing of the current and incoming stock. A qualified 
herd health management specialist on infectiology 
should direct such procedures plus all appropriate 
additional measures. Β 
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